Tengion successor RegenMedTX raises $4m

RegenMedTX, which acquired the assets of bankrupt organ regeneration technology company Tengion (NSDQ:TNGN) in March, said it raised more than $4 million from a syndicate of 27 unnamed investors.

Winston-Salem, N.C.-based RegenMedTX is led by former Tengion CSO Tim Bertram and CTO Deepak Jain, the Winston-Salem Journal reported. Tengion, which pulled the plug in December 2014 after seeking but failing to find a buyer, was acquired for $22 million after declaring Chapter 7 bankruptcy Dec. 29, 2014.

According to a regulatory filing yesterday with the SEC, RegenMedTX added $2.9 million to the $1.5 million it reported raising in January, taking the total raised to $4.4 million of a hoped-for $6.4 million.

Tengion was founded in 2003 by Dr. Anthony Atala, head of the Wake Forest Institute for Regenerative Medicine. It raised $40 million in a 2010 IPO and another $74 million in a sale of stock announced in August 2013.

Tengion’s technology is designed to regenerate a range of native-like organs and tissues to delay or eliminate the need for chronic disease therapies and organ transplantation. Its Neo-Kidney Augment was in Phase 1 clinical trials in Sweden and the U.S. as of September 2014, when it tapped Jefferies “to assist it with reviewing and structuring potential strategic transactions.”

The post Tengion successor RegenMedTX raises $4m appeared first on MassDevice.

from MassDevice http://ift.tt/1Ncetju